Results 211 to 220 of about 45,933 (222)

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

European Urology, 2016
Nizar Tannir, Priya Rao, Jose A Karam
exaly  

A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Annals of Oncology, 2010
Patrick Schöffski, Jean-Yves Blay, N Hollaender   +2 more
exaly  

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Annals of Oncology, 2015
E Legouffe, E Pujade-Lauraine, S Abadie-Lacourtoisie   +2 more
exaly  

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

Annals of Oncology, 2011
P Fasching, J -U Blohmer, C Hanusch
exaly  

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

Annals of Oncology, 2017
Philipp A Schnabel, Christian Sieder
exaly  

Clinical Pharmacokinetics of Everolimus

Clinical Pharmacokinetics, 2012
Michael Manns, Gabriele I Kirchner
exaly  

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Annals of Oncology, 2018
Luigi Rigacci, J Kuruvilla, M Voi
exaly  

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

Annals of Oncology, 2015
Eric Deutsch, Sofia Rivera, Antonin Levy
exaly  

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Annals of Oncology, 2012
Olivier Feron, Jean-Pascal Machiels, Emmanuel Seront   +2 more
exaly  

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)†

Annals of Oncology, 2016
Matthew P Goetz, C Erlichman, N R Foster
exaly